Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868998 · ClinicalTrials.gov registry record · Phase 2
GTX Regimen for Biliary Cancers
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00868998: Clinical Trial Phase 2 study, sponsored by Columbia University.
NCT00868998 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00868998, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a study for patients with advanced cancer of the biliary tree, such as cholangiocarcinoma. They will be treated with a chemotherapy regimen consisting of Gemcitabine, Taxotere, and Xeloda every 21 days for at least 9 weeks. Treatment will continue until their cancer progresses. This chemotherapy regimen has been used in pancreatic cancer and there is reason to believe that it will be effective for cancers of the biliary tree as well.
Primary Outcome
Data was not analyzed due to poor accrual.
Interventions
- DRUG Gemcitabine, docetaxel, and capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Why NCT00868998 stopped before completion
NCT00868998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, docetaxel, and capecitabine is the first listed.
NCT00868998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00868998 about?
NCT00868998 is a clinical study titled "GTX Regimen for Biliary Cancers". This is a study for patients with advanced cancer of the biliary tree, such as cholangiocarcinoma. They will be treated with a chemotherapy regimen consisting of Gemcitabine, Taxotere, and Xeloda every 21 days for at least 9 weeks. Treatment will continue until their cancer progresses. This chemothe...
What is the current status of trial NCT00868998?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2005-08. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00868998?
The interventions under investigation include: Gemcitabine, docetaxel, and capecitabine (DRUG).
Who is sponsoring clinical trial NCT00868998?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00868998's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia